Related Party Transactions	9 Months Ended
Sep. 30, 2018
Related Party Transaction, Due from (to) Related Party [Abstract]
Related Party Transactions	Related Party Transactions Exela PharmSci, Inc. We entered into a commercialization agreement with Exela in 2007. Under the license agreement, as amended, we and Exela cross-licensed certain technology relating to the manufacture of argatroban, an API, in exchange for rights to certain sublicensing fees or development payments and profit sharing. The revenue sharing arrangement was terminated in December 2017. Thomas R. Baruch, one of our directors, serves on the board of directors of Exela, and is a retired general partner in Presidio Partners 2007, LP which owns over 10% of Exela’s outstanding capital stock. As such, Mr. Baruch has an indirect pecuniary interest in the shares of Exela held by Presidio Partners 2007, L.P. We recognized no revenue for the three and nine months ended September 30, 2018, compared to $0.1 million and $0.8 million in revenues for the three and nine months ended September 30, 2017, respectively, shown in the unaudited condensed consolidated statement of operations as research and development revenue. We had zero and $1.6 million of receivables from Exela at September 30, 2018 and December 31, 2017, respectively. AstraZeneca PLC Pam P. Cheng, a member of our board of directors, joined AstraZeneca PLC as Executive Vice President, Operations and Information Technology in June 2015. We sell biocatalyst products to AstraZeneca PLC, to Alfa Aesar, which is a purchasing agent of AstraZeneca PLC, and also to Asymchem Life Science Co, Ltd, which is a contract manufacturer for AstraZeneca PLC. In the three and nine months ended September 30, 2018, we recognized de minimis and $0.3 million in revenue from AstraZeneca PLC, compared to de minimis and $52 thousand in the three and nine months ended September 30, 2017, respectively. We recognized zero and de minis revenue from Asymchem in the three and nine months ended September 30, 2018, respectively, compared to $13 thousand in revenue in the three and nine months ended September 30, 2017. We recognized no revenue from Alfa Aesar in the three and nine months ended September 30, 2018 and 2017, respectively. At September 30, 2018 and December 31, 2017, we had $3 thousand and $86 thousand of accounts receivables from AstraZeneca, PLC, respectively, zero and $0.4 million of accounts receivables from Alfa Aesar, respectively, and no accounts receivables from Asymchem.

Related Party Transactions

Exela PharmSci, Inc.

We entered into a commercialization agreement with Exela in 2007. Under the license agreement, as amended, we and Exela cross-licensed certain technology relating to the manufacture of argatroban, an API, in exchange for rights to certain sublicensing fees or development payments and profit sharing. The revenue sharing arrangement was terminated in December 2017.

Thomas R. Baruch, one of our directors, serves on the board of directors of Exela, and is a retired general partner in Presidio Partners 2007, LP which owns over 10% of Exela’s outstanding capital stock. As such, Mr. Baruch has an indirect pecuniary interest in the shares of Exela held by Presidio Partners 2007, L.P.

We recognized no revenue for the three and nine months ended September 30, 2018, compared to $0.1 million and $0.8 million in revenues for the three and nine months ended September 30, 2017, respectively, shown in the unaudited condensed consolidated statement of operations as research and development revenue. We had zero and $1.6 million of receivables from Exela at September 30, 2018 and December 31, 2017, respectively.

AstraZeneca PLC

Pam P. Cheng, a member of our board of directors, joined AstraZeneca PLC as Executive Vice President, Operations and Information Technology in June 2015. We sell biocatalyst products to AstraZeneca PLC, to Alfa Aesar, which is a purchasing agent of AstraZeneca PLC, and also to Asymchem Life Science Co, Ltd, which is a contract manufacturer for AstraZeneca PLC.

In the three and nine months ended September 30, 2018, we recognized de minimis and $0.3 million in revenue from AstraZeneca PLC, compared to de minimis and $52 thousand in the three and nine months ended September 30, 2017, respectively. We recognized zero and de minis revenue from Asymchem in the three and nine months ended September 30, 2018, respectively, compared to $13 thousand in revenue in the three and nine months ended September 30, 2017. We recognized no revenue from Alfa Aesar in the three and nine months ended September 30, 2018 and 2017, respectively. At September 30, 2018 and December 31, 2017, we had $3 thousand and $86 thousand of accounts receivables from AstraZeneca, PLC, respectively, zero and $0.4 million of accounts receivables from Alfa Aesar, respectively, and no accounts receivables from Asymchem.